Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

Sponsor
Alona Zer
Study ID
NCT03219671
Phase
PHASE2
Status
Unknown

Conditions

  • Classic Kaposi Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    nivolumab 240mg every 2 weeks
  • Ipilimumab — DRUG
    ipilimumab 1 mg/kg every 6 weeks

Study Details

A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)

Key Dates

Start date
Apr 1, 2018
Status verified
Dec 2018
Primary completion
Sep 1, 2020
Completion
Sep 1, 2022

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: nivolumab plus ipilimumab
    nivolumab 240mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks

Primary Outcome Measure

ORR [ Time Frame: 6-months ]

Central Contacts